Method of treating heart failure with modified relaxin polypeptides

Patent metadata

Field	Value
Publication number	US-9962450-B2
Application number	US-201615239277-A
Country	US
Kind code	B2
Filing date	Aug 17, 2016
Priority date	Aug 17, 2010
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

Modified relaxin polypeptides and their uses thereof are provided.

First claim

What is claimed is:

1. A method of treating heart failure in a patient in need thereof, comprising administering to said patient an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein said relaxin A chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 4, and said relaxin B chain polypeptide has a sequence at least 95% identical to SEQ ID NO: 5 or SEQ ID NO: 6, and said non-naturally encoded amino acid is substituted in said A chain polypeptide at residue 1; and
(b) the non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule, wherein said non-naturally encoded amino acid comprises a first functional group and the linker, polymer, or biologically active molecule comprises a second functional group, wherein the first functional group and second functional group are not identical and each comprise a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group, and the resultant covalent linkage created by the reaction of the first and second functional groups comprises an oxime linkage or a triazole.

2. The method of claim 1 , wherein said non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule by an oxime linkage.

3. The method of claim 1 , wherein said non-naturally encoded amino acid has the structure:

wherein the R group is a substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.

4. The method of claim 3 , wherein said non-naturally encoded amino acid is selected from a para-substituted, ortho-substituted, or meta-substituted phenylalanine comprising a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group.

5. The method of claim 4 , wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine or para-azido-L-phenylalanine.

6. The method of claim 1 , wherein said modified relaxin polypeptide is recombinant, is produced in a eukaryotic host cell, is produced in a non-eukaryotic host cell, or is produced by in vitro translation.

7. The method of claim 1 , wherein the non-naturally encoded amino acid is linked to a polymer.

8. The method of claim 7 , wherein said polymer is a water soluble polymer.

9. The method of claim 8 , wherein said water soluble polymer comprises poly(ethylene glycol) having an average molecular weight of between 0.1 kDa and 100 kDa.

10. The method of claim 1 , wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine.

11. A method of treating heart failure in a patient in need thereof, comprising administering to said patient an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the relaxin polypeptide comprises a relaxin A chain polypeptide and a relaxin B chain polypeptide, wherein the relaxin A chain polypeptide comprises SEQ ID NO: 4 containing a substitution of an amino acid with a non-naturally encoded amino acid at residue 1 and the relaxin B chain polypeptide comprises SEQ ID NO: 6 or SEQ ID NO: 5;
(b) said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine and said non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule.

12. The method of claim 11 , wherein the non-naturally encoded amino acid is linked to a polymer.

13. The method of claim 11 , wherein said polymer is a water soluble polymer.

14. The method of claim 13 , wherein said polymer comprises poly(ethylene glycol) having an average molecular weight of between 0.1 kDa and 100 kDa.

15. The method of claim 11 , wherein said relaxin B chain polypeptide comprises SEQ ID NO: 6.

16. A method of treating heart failure in a patient in need thereof, comprising administering to said patient an effective amount of a biologically active modified relaxin polypeptide comprising a non-naturally encoded amino acid, wherein:
(a) the relaxin polypeptide comprises a relaxin A chain polypeptide of SEQ ID NO: 4 and a relaxin B chain polypeptide of SEQ ID NO: 5 or SEQ ID NO: 6 which relaxin A and B chain polypeptide sequences contain up to one natural amino acid substitution and further contain one non-naturally encoded amino acid substitution in said A chain polypeptide at residue 1; and
(b) said non-naturally encoded amino acid is linked to a linker, polymer, or biologically active molecule by an oxime linkage or a triazole linkage.

17. The method of claim 16 , wherein said non-naturally encoded amino acid has the structure:

wherein the R group is a substituent other than the side chain found in alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine.

18. The method of claim 17 , wherein said non-naturally encoded amino acid comprises a phenylalanine analog or derivative.

19. The method of claim 18 , wherein said non-naturally encoded amino acid is selected from a para-substituted, ortho-substituted, or meta-substituted phenylalanine comprising a carbonyl group, an aminooxy group, a hydrazide group, a hydrazine group, a semicarbazide group, an azide group, or an alkyne group.

20. The method of claim 19 , wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine or para-azido-L-phenylalanine.

21. The method of claim 20 , wherein said non-naturally encoded amino acid comprises para-acetyl-L-phenylalanine.

Assignees

• Ambrx Inc

Inventors

• Kraynov Vadim
• Knudsen Nick
• Hewet Amha
• De Dios Kristine
• Pinkstaff Jason
• Sullivan Lorraine

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/08

  Vasodilators for multiple indications · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title